Obstructive Lung Diseases: COPD II |

Blocking CCL20 Can Attenuate the Impact of Dendritic Cells on COPD FREE TO VIEW

Desheng Sun, MD; Yao Ouyang; Yanhui Gu; Hongyan Liu
Author and Funding Information

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Copyright 2016, American College of Chest Physicians. All Rights Reserved.

Chest. 2016;149(4_S):A383. doi:10.1016/j.chest.2016.02.398
Text Size: A A A
Published online


SESSION TYPE: Original Investigation Poster

PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM

PURPOSE: To investigate the expressions of dendritic cells (DCs) and its chemokine receptor CCR6 in the lungs of rats with COPD and the effect of anti-CCL20 therapy on it.

METHODS: 18 Wistar rats were randomized into three groups: control, COPD model and CCL20 monoclonal antibody treated. In the latter two groups, COPD was induced by cigarette smoke exposure for four weeks and intratracheal LPS solution twice totally. CCL20 monoclonal antibody was injected intraperitoneally in the last group on the first day. All animals were sacrificed at the 29th day. Then pathomorphology of rats' lung and bronchiole were investigated by HE staining. The content of CCR6 in the BALF was analyzed with ELISA. DC distribution in rats' lung was evaluated by immunohistochemistry for OX62.

RESULTS: Rats in the latter two groups expressed lassitude and less activities, and their weights were lower than the control-group. The HE staining results of the COPD models suggest similar changes of pathology to those of COPD patients. DCs and CCR6 were significantly increased in lungs with COPD compared with the controls, while, compared with these models, DCs and CCR6 in the lungs of the CCL20 monoclonal antibody treated group were significantly reduced.

CONCLUSIONS: The interaction of CCR6 with its ligand CCL20 contributes to the impact of DCs on the pathogenesis of COPD, but blocking CCL20 can attenuate this impact.

CLINICAL IMPLICATIONS: This study would provide the new view on the pathogenesis and the treatment targets of COPD.

DISCLOSURE: The following authors have nothing to disclose: Desheng Sun, Yao Ouyang, Yanhui Gu, Hongyan Liu

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543